Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. - Wikidata - awgldk - TriplyDB

Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.

Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.

http://www.wikidata.org/entity/Q40355980

about

Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1 The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.Pathways to tamoxifen resistance.EGFR associated expression profiles vary with breast tumor subtype Activation of estrogen receptor-alpha by E2 or EGF induces temporally distinct patterns of large-scale chromatin modification and mRNA transcription.Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.Tamoxifen for induction of Cre-recombination may confound fibrosis studies in female mice.EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.Estrogen regulation of anti-apoptotic Bcl-2 family member Mcl-1 expression in breast cancer cells Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers.EGFR signaling in breast cancer: bad to the bone.Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs.Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer MicroRNA-mediated drug resistance in breast cancer.Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation.Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice.Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Evaluation of the current knowledge limitations in breast cancer research: a gap analysis A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients.The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop.Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development.Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305.Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.AR Signaling in Breast Cancer.

P2860

Q27001260-5241340B-70DC-4D27-96DE-97939768A92C Q27694612-BE5CE754-9DA0-4304-855A-2801901DF361 Q28569016-5A3A98D6-BFF2-485A-8330-18F6553046EE Q30425478-1A3CDB7D-8A69-4051-BD1A-76FE5DC1F5B4 Q30436239-833AB483-A828-4B62-A992-B203D88EDCF3 Q30441001-63E036E2-D4E3-4BD8-A0E0-497497E28D0E Q33292502-8377437B-D05C-4A94-B482-5DB092CAF25C Q33338444-64B69DA0-F661-49DB-802E-E21829F37E66 Q33648503-D5BCF8B7-F3B6-4DC0-963A-B4AEE3DA1C1F Q33714763-B84C81E1-1CAE-4DE0-9C05-7423BBDABFB8 Q33793142-A794B621-01F0-4C5F-8B66-512979D640F5 Q33817324-7BB8BA74-94C4-4096-B8A1-416E499DE7C7 Q34160418-83B1FAF1-31DE-437F-9A1F-F327FB0054D1 Q34348232-F92D3435-7401-4916-91B7-DF1B213784B6 Q34484372-A1C96CCB-0578-4C1D-896D-371198AAB8C9 Q34619220-DA1CB3A7-1F4E-4ADF-B4F8-25290DB335CB Q35165126-3CA93D46-1CC8-4BCB-841F-CFD01EC54F30 Q35558138-4C38C933-3A1A-4E9D-814E-99FB7E6EA2B7 Q35689023-0E685AA2-5C82-4E41-8B5C-28D57FF6255B Q35777328-FEAA4E36-2495-4547-9B46-A96E46B428D3 Q35786706-D157E3AE-4852-41A9-82A4-31222D9DF9DD Q35808483-3787DB3B-5DA9-4AD5-86A6-5D26A44610F0 Q36127379-FEA403DE-CDC2-4AD9-8D47-C90DA12C09FC Q36172210-9287E6A1-9079-4AC0-9DC9-7F3ACFCDCEEE Q36393289-51B2B009-64EB-40A7-9E21-1784D14B3671 Q36568006-3B3A346A-DF09-46D9-8FD6-70D4C6F58193 Q36589865-13C88B4D-ACF1-4676-A23A-66B8CACB766E Q36642923-CB75C568-79E5-440E-824B-6CBF118EC6F2 Q36678664-90E5E269-1EE5-45A3-9D84-A62CD9743B83 Q36903310-2AA73109-1F8B-46C7-8F9E-68F354D314FD Q36933778-17A1557C-D39C-4D49-9D4C-90F23D319BB9 Q36955067-7F203F92-FD70-43D7-B9A3-076D654152CD Q37158137-96351399-8493-42FE-B9E9-9E7CFE624E67 Q37206267-EA65B3AD-309A-4979-B28A-EF3F66D9B85D Q37328397-11A10790-1F9C-47D8-992A-EE7115CA843A Q37393002-F6691579-CE7E-42FC-A515-A965226C3520 Q37467189-1E8C00F3-3AAA-449B-839A-9002A25FC989 Q37632309-924CE738-95A0-4581-AB26-C20C9BB88655 Q37690245-F4312FE0-D138-465F-BD5F-B32F0C0B9C07 Q37721492-1F649E5D-48BF-4260-90E0-2DF16D65D4E7

P2860

Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.

http://www.wikidata.org/entity/Q40355980

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Bidirectional cross talk betwe ...... es tamoxifen-resistant growth.

@en

type

label

Bidirectional cross talk betwe ...... es tamoxifen-resistant growth.

@en

prefLabel

Bidirectional cross talk betwe ...... es tamoxifen-resistant growth.

@en

P1433

Q40355980-925DB410-F5F6-4ACE-B5A4-DD7E2E105837

P1476

Q40355980-B7564A6A-801F-4CA2-92AD-C35BB3EE1BB8

P2093

Q40355980-0031E9D7-BABE-4905-89F1-3763B1B0AA76

Q40355980-07A1914C-8F82-46B2-BB61-EE58A371B1D2

Q40355980-1D7AFFDC-1468-4532-BFCC-40BA1015ED49

Q40355980-3595868A-D7A2-4045-AEB2-A8C95EDE5DFB

Q40355980-711D9663-D746-4EDB-852B-FC2D232B37E5

Q40355980-717AF815-6A14-4336-BCEB-1262C6654094

Q40355980-DA3763FD-5515-45E0-AF85-731805DF6C9D

P2860

Q40355980-1E4DBA59-BF07-4FB8-947C-A8FB6FFD7A3A

Q40355980-7A7D9179-D049-450D-8B17-ECE30951C1FB

Q40355980-7C50E9B9-A335-49BA-BE1A-D911656FD3EB

Q40355980-9DA279A2-181F-41AE-B078-3C57439B78DE

Q40355980-A36D3796-3B33-4988-8220-94EF69696B5C

Q40355980-A3F741BB-4D10-49EB-98BB-42BD77BAFC63

Q40355980-D73398F5-7265-4CA3-A791-D835C110D874

Q40355980-D91A264D-67C8-45B5-8395-A223AB3D494D

Q40355980-EBF9ECA7-1EBD-42CE-9986-1E240F3861B8

Q40355980-F0E160BB-BF07-46B5-A8AA-95F66497486B

P2888

Q40355980-25127D10-7F9D-49BB-816A-73C485835626

P304

Q40355980-24FA421C-83D2-4B3A-B1BE-EF796600E62C

P31

Q40355980-8FAEBD97-424B-4CF6-8369-258AB11B6ECF

P356

Q40355980-5E2732AE-4EDB-4E6C-A63F-27FE3637EB96

P407

Q40355980-5A9CD933-37EB-49D6-A363-B5CDC61209DC

P433

Q40355980-EB0E2534-22EC-4733-A1EA-B1B0C61D93BA

P478

Q40355980-0C4D8279-4AB5-492C-9737-C1DA4CE95857

P50

Q40355980-3B4B1356-D320-46AB-A8B0-C4329CA231E5

P577

Q40355980-629D0B04-A784-4A83-8699-9F3E917E0B8C

P6179

Q40355980-7DEABDFA-5BB5-43CD-8842-D3B14073984D

P698

Q40355980-09B19B1B-196B-4118-970F-E4C90A3A7B95

P356

S10549-005-9070-2

P1433

Breast Cancer Research and Treatment

P1476

Bidirectional cross talk betwe ...... tes tamoxifen-resistant growth

@en

P2093

Barrow D

http://www.w3.org/2001/XMLSchema#string

Britton DJ

http://www.w3.org/2001/XMLSchema#string

Giles M

http://www.w3.org/2001/XMLSchema#string

Hutcheson IR

http://www.w3.org/2001/XMLSchema#string

Knowlden JM

http://www.w3.org/2001/XMLSchema#string

McClelland RA

http://www.w3.org/2001/XMLSchema#string

Nicholson RI

http://www.w3.org/2001/XMLSchema#string

P2860

pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167

Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.

Oestrogen receptor: a stable phenotype in breast cancer

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line.

Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line.

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.

Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity.

Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells.

P2888

s10549-005-9070-2

P304

131-146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-005-9070-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011886505

http://www.w3.org/2001/XMLSchema#string

P698

16261397

http://www.w3.org/2001/XMLSchema#string